The Womed Leaf device received CE mark back in 2021. Credit: Helena Nechaeva via Shutterstock.

France-based FemTech company Womed has announced positive results from a clinical trial of its Womed Leaf device, deeming it effective for the treatment and prevention of bonding of the uterine walls after surgical intervention – one of the main causes of female infertility. 

Intrauterine adhesions (IUAs), sometimes known as Asherman’s syndrome, are bands of scar tissue that form inside the uterus and can cause menstrual abnormalities or infertility. They often result from uterine surgeries or infections and can require medical intervention to remove the adhesions and restore fertility. 

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The Womed Leaf device, which received CE mark back in 2021, is composed of a polymer film, serving as a protective barrier against IUAs. Inserted like an intrauterine device (IUD) at the end of the uterine procedure, it expands within the uterine cavity, preventing the direct contact of the uterine walls against each other for a week. Following this, it is naturally discharged. 

In the PREG2 clinical trial, 160 women with severe or moderate IUA underwent adhesiolysis surgery, a procedure used to remove scar tissue bands between abdominal organs. The participants were randomly assigned to receive a Womed Leaf or no intervention.

At the six-week follow-up, women who received Womed Leaf were 2.4 times less likely to develop adhesions compared to the control group. All efficacy endpoints favoured the Womed Leaf, with no serious adverse events reported from the trial. 

Womed co-founder and CEO Gonzague Issenmann said that the device will be marketed through commercial partners.  

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Issenmann commented: “Womed has achieved an unprecedented feat and we are very proud to be the first team to offer a solution to women with scarred uterus in their exhausting journey to become pregnant.” 

Compared to the overall health sector, FemTech remains one of the lowest-funded subsets. This can be pinned to several reasons, including a lack of research into women’s health, and lack of awareness.